Medtronic, a global leader in healthcare technology, has received FDA approval for its Percept™ RC neurostimulator, now available in India. This device is the smallest and thinnest dual-channel neurostimulator in the market for Deep Brain Stimulation (DBS), representing the latest innovation in the Percept™ family. The Percept™ RC adds to Medtronic’s existing range of neurostimulators.
The Percept™ systems are the only DBS devices with integrated sensing capabilities, allowing doctors to provide personalized treatments for patients with movement disorders such as Parkinson’s disease, essential tremor, dystonia, and epilepsy.
Featuring BrainSense™ technology, the Percept™ RC records and analyzes brain signals, providing critical insights that enable healthcare providers to adjust and customize treatments according to each patient’s evolving needs.
The rechargeable battery, powered by Medtronic’s patented technology, offers a service life of over 15 years with minimal battery fade, ensuring long-lasting performance. In addition, the Percept™ RC can be recharged quickly, reaching 10% to 90% in less than an hour, providing both convenience and reliability for patients.
Prateek Tiwari, Senior Director of Neuroscience and Specialty Therapies at Medtronic India, expressed excitement about bringing this advanced DBS technology to India. He stated, “This groundbreaking solution meets the growing demand for advanced healthcare technologies and is poised to transform the treatment of complex neurological disorders. With its ability to provide data-driven, personalized therapy, the new rechargeable Percept™ RC with BrainSense™ technology offers significant potential to enhance patient outcomes, offering new hope for those managing chronic neurological conditions. We are committed to enabling healthcare providers in India to set a new standard in precision care and improving patients’ quality of life.”
Deep Brain Stimulation (DBS) involves a surgically implanted device, similar to a cardiac pacemaker, that sends electrical signals through fine wires to targeted areas of the brain affected by neurological conditions like Parkinson’s disease.
It is estimated that nearly 70% of DBS patients need an MRI as part of their care. Medtronic offers full-body MR Conditional DBS systems, ensuring safe scans anywhere on the body when following specific guidelines. The Percept™ RC provides greater flexibility for patients requiring 3T scans and boasts top-tier 1.5T MRI scan labeling. Notably, Medtronic’s DBS systems are the only ones that allow patients to have stimulation in bipolar mode during an MRI. Furthermore, the Percept™ devices are designed for future software updates without the need to replace the neurostimulator itself.